Nooglutyl
Russian AMPA-PAM research compound, plasticity enhancer.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.
Pharmacology
Contents
WHAT IS NOOGLUTYL?
Detailed overview
Nooglutyl (NSG, ONK-10, N-5-oxynicotinoyl-L-glutamic acid) is an experimental compound developed at the Pharmacology Institute of the Russian Academy of Sciences (Moscow), structurally related to Picamilon. AMPA receptor positive allosteric modulator – with substantially stronger AMPA binding affinity than Noopept (PMID 21476267). Unique data: benzodiazepine-withdrawal anxiety reduction in animal models without touching the GABA system; preservation of post-trauma mitochondrial oxidative phosphorylation (ATP-synthesis protection; PMID 9621180); anti-aging pro-cognitive effects in accelerated-aging models (PMID 18078032); enhanced neuroprotection when co-administered with Nimodipine. No human Phase data; rare on Western markets.
Mechanism
AMPA-PAM (glutamatergic)
Half-life
No published human data
Legal status
Russian preclinical only
Receptor profile
- AMPA glutamate receptorsStrong
- Synaptic plasticity / LTPModerate
- Antiamnesic / antihypoxic pathwaysModerate
Safety
Side effects, stop signs, contraindications
Side effects · 6
- Limited human safety data: profile based mainly on animal studies and anecdotes
- Mild anxiety and restlessness reported anecdotally (glutamatergic/stimulating character)
- Physical stimulation and overstimulation at higher doses (above ~20 mg)
- Theoretical risk typical of AMPA-enhancing compounds: headache, increased neuronal excitability
- Sleep disturbance and difficulty falling asleep if taken in late afternoon or evening
- Long-term safety unknown; chronic adverse effects not characterized
Contraindications · 5
- Pregnancy and breastfeeding: no safety data, avoid
- Epilepsy or low seizure threshold: AMPA/glutamatergic enhancement may theoretically raise seizure risk
- Anxiety disorders: the stimulating character may worsen symptoms
- Combining with other glutamatergic or stimulant nootropics requires caution (additive overstimulation)
- Not an approved drug, no human dosing standard; research chemical only, use is experimental
Related Nootropics
Same therapeutic category
FAQ
FAQ
Nooglutyl is an experimental compound developed at a Russian research institute that strengthens one of the brain's excitatory signaling systems (the AMPA receptor), so it's studied as a plasticity enhancer, meaning something meant to support the brain's ability to learn and adapt. Based on the source, this is a purely research-stage, experimental substance with no broad, reliable human data available. In practice it's a lab compound, not an established, well-tested supplement.
Telegram
Have a question about Nooglutyl?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.